Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
6.12
+0.10 (1.66%)
At close: Nov 20, 2024, 4:00 PM
6.42
+0.30 (4.90%)
After-hours: Nov 20, 2024, 6:40 PM EST
Lexeo Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | - | - | 0.65 | 1.66 | 0.52 |
| Revenue Growth (YoY) | - | - | -60.53% | 219.59% | - |
| Cost of Revenue | 63.94 | 53.13 | 49.16 | 45.12 | 4.32 |
| Gross Profit | -63.94 | -53.13 | -48.51 | -43.46 | -3.8 |
| Selling, General & Admin | 29.42 | 15.38 | 12 | 7.17 | 0.79 |
| Operating Expenses | 29.42 | 15.38 | 12 | 7.17 | 0.79 |
| Operating Income | -93.36 | -68.51 | -60.51 | -50.64 | -4.59 |
| Interest Expense | -0.16 | -0.21 | -0.09 | - | -0.15 |
| Interest & Investment Income | 7.19 | 2.87 | 1.33 | 0.02 | - |
| Other Non Operating Income (Expenses) | -0.02 | -0.01 | -0 | - | 0 |
| EBT Excluding Unusual Items | -86.34 | -65.86 | -59.28 | -50.62 | -4.73 |
| Gain (Loss) on Sale of Investments | -0.26 | -0.53 | - | - | - |
| Other Unusual Items | - | - | - | - | -0.42 |
| Pretax Income | -86.6 | -66.39 | -59.28 | -50.62 | -5.15 |
| Net Income | -86.6 | -66.39 | -59.28 | -50.62 | -5.15 |
| Net Income to Common | -86.6 | -66.39 | -59.28 | -50.62 | -5.15 |
| Shares Outstanding (Basic) | 28 | 5 | 2 | 2 | 1 |
| Shares Outstanding (Diluted) | 28 | 5 | 2 | 2 | 1 |
| Shares Change (YoY) | 1601.39% | 228.42% | 5.00% | 7.72% | - |
| EPS (Basic) | -3.13 | -12.40 | -36.36 | -32.60 | -3.57 |
| EPS (Diluted) | -3.13 | -12.40 | -36.36 | -32.60 | -3.57 |
| Free Cash Flow | -67.36 | -59.61 | -55.23 | -44.37 | -3.13 |
| Free Cash Flow Per Share | -2.44 | -11.13 | -33.88 | -28.58 | -2.17 |
| Operating Margin | - | - | -9252.14% | -3055.94% | -884.86% |
| Profit Margin | - | - | -9063.76% | -3055.04% | -993.83% |
| Free Cash Flow Margin | - | - | -8445.26% | -2677.73% | -604.35% |
| EBITDA | -92.73 | -67.94 | -60.24 | -50.62 | - |
| D&A For EBITDA | 0.63 | 0.58 | 0.27 | 0.01 | - |
| EBIT | -93.36 | -68.51 | -60.51 | -50.64 | -4.59 |
| Revenue as Reported | - | - | 0.65 | 1.66 | 0.52 |
Source: S&P Capital IQ. Standard template.
Financial Sources.